| Class / Patent application number | Description | Number of patent applications / Date published |
|---|
| 435332000 | Immunoglobulin or antibody binds a microorganism or normal or mutant component or product thereof (e.g., animal cell, cell surface antigen, secretory product, etc.) | 39 |
| 20090197330 | ANTI-CD20 MONOCLONAL ANTIBODY - Disclosed is a monoclonal antibody capable of inducing a specific biological reaction through the binding of the monoclonal antibody to a CD20 antigen on the surface of a cell. A monoclonal antibody having a high binding affinity to an extracellular epitope of a CD20 antigen and also having biological activities including a cell growth inhibitory activity is cloned. The monoclonal antibody is chimerized or humanized to develop a therapeutic agent for a disease in which B cells are involved. | 08-06-2009 |
| 20110223658 | MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP) | 09-15-2011 |
| 20120225478 | ANTI-AMYLOID BETA ANTIBODIES AND THEIR USE - The present invention relates to antibody molecules capable of specifically recognizing two regions of the β-A4 peptide, wherein the first region comprises the amino acid sequence AEFRHDSGY as shown in SEQ ID NO: 1 or a fragment thereof and wherein the second region comprises the amino acid sequence VHHQKLVFFAEDVG as shown in SEQ ID NO: 2 or a fragment thereof. Furthermore, nucleic acid molecules encoding the inventive antibody molecules and vectors and hosts comprising said nucleic acid molecules are disclosed. In addition, the present invention provides for compositions, preferably pharmaceutical or diagnostic compositions, comprising the compounds of the invention as well as for specific uses of the antibody molecules, nucleic acid molecules, vectors or hosts of the invention. | 09-06-2012 |
| 20120329149 | HUMANIZED ANTIBODY - The present invention is related to chimeric and humanized antibody and to methods and compositions for the therapeutic and diagnostic use in the treatment of amyloidosis, a group of disorders and abnormalities associated with amyloid protein such as Alzheimer's disease. | 12-27-2012 |
| 20130252327 | Methods Of Gene Amplification And Expression - Disclosed are methods relating to amplification and expression of a nucleic acid sequence encoding a polypeptide of interest in recombinant cells, and cell lines and polypeptides produced from such methods. The methods disclosed herein permit the amplification of cell lines that express a polypeptide of interest in a relatively short period of time through the use of a bioreactor. | 09-26-2013 |
| 20130344593 | METHOD FOR THE PRODUCTION OF HYBRIDOMA CELL LINES PRODUCING MONOCLONAL ANTIBODIES CAPABLE TO SPECIFICALLY BINDING TO A HUMAN C44-FRAGMENT OF AGRIN - A method for the production of a hybridoma cell lines producing monoclonal antibodies capable to specifically binding to a human C44-fragment of agrin, comprising administering to wild-type-mice an immunizing amount of C44y≧4-fragment of agrin, isolating antibody producing cells from the immunized mice, fusing them with a myeloma cell line, growing the fused cells in a selection medium, screening the antibodies in the supernatants of hybridoma cells for binding to C44-fragment of agrin and isolating the hybridoma cells producing the desired monoclonal antibodies | 12-26-2013 |
| 435334000 | Binds a receptor (e.g., transferrin receptor, Fc receptor, dihydropyridine receptor, IL-2 receptor, etc.) | 13 |
| 20090047735 | Antibodies Against Human G-Protein Chemokine Receptor (CCR5) HDGNR10 - The present invention relates to a novel human protein called Human G-protein Chemokine Receptor (CCR5) HDGNR10, and isolated polynucleotides encoding this protein. The invention is also directed to human antibodies that bind Human G-protein Chemokine Receptor (CCR5) HDGNR10 and to polynucleotides encoding those antibodies. Also provided are vectors, host cells, antibodies, and recombinant methods for producing Human G-protein Chemokine Receptor (CCR5) HDGNR10 and human anti-Human G-protein Chemokine Receptor (CCR5) HDGNR10 antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing and treating diseases, disorders, and/or conditions related to this novel human protein and these novel human antibodies. | 02-19-2009 |
| 20100081195 | Modified Host Cells and Uses Thereof - The present disclosure provides compositions and methods comprising cells producing glycoproteins with variant glycosylation patterns. The methods and compositions may be used in producing antibodies and proteins of therapeutic value. | 04-01-2010 |
| 20100190247 | Methods of Generating Variant Proteins with Increased Host String Content - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 07-29-2010 |
| 20110053265 | Cell Culture Performance with Betaine - This invention relates generally to the field of cell culture. More particularly, the invention relates to improving viability of recombinant cell cultures and the yields of secreted polypeptides therefrom by the addition of betaine to the tissue culture medium. | 03-03-2011 |
| 20110236969 | METHODS OF GENERATING VARIANT PROTEINS WITH INCREASED HOST STRING CONTENT AND COMPOSITIONS THEREOF - The present invention relates to novel methods for generating variant proteins with increased host string content, and proteins that are engineered using these methods. | 09-29-2011 |
| 20110281348 | AGONIST ANTI-TRKC ANTIBODIES AND METHODS USING SAME - The invention concerns agonist anti-trkC antibodies, polypeptides, and polynucleotides encoding the same. The invention further concerns use of such antibodies, polypeptides and/or polynucleotides in the treatment and/or prevention of neuropathies, such as sensory neuropathies, including taxol-induced sensory neuropathy, cisplatin-induced sensory neuropathy, and pyridoxine-induced sensory neuropathy. | 11-17-2011 |
| 20130023047 | Nucleic Acids Encoding Humanized Anti-CD40 Antibodies - Provided are humanized anti-CD40 antibodies and antigen-binding fragments and methods for treating disease characterized by expression of CD40 antigen. | 01-24-2013 |
| 20130078717 | BINDING MEMBERS-513 - This invention relates to binding members, especially antibody molecules, specific for interleukin 1 receptor 1 (IL-1R1). For example, isolated binding members specific for IL-1R1 which competes with IL-1 and IL-1Ra for binding to IL-1R1 and binds Il-1R1 with a K | 03-28-2013 |
| 20130109087 | Transgenic Animal with Enhanced Immune Response and Method for the Preparation Thereof | 05-02-2013 |
| 20130316450 | Compositions and Methods for Diagnosing and Treating Cancer - Isolated antibodies that specifically bind the human MET Receptor and inhibit MET signaling are described. Also described are methods of treating cancer, the methods comprising administering a therapeutically effective amount of the provided MET antibodies and combinations thereof. | 11-28-2013 |
| 20140099708 | Anti-IL12Rbeta1 Antibodies And Their Use In Treating Autoimmune And Inflammatory Disorders - The present invention relates to antibodies that specifically bind to IL12Rβ1, the non-signal transducing chain of both the heterodimeric IL12 and IL23 receptors. The invention more specifically relates to specific antibodies that are IL12 and IL23 receptor antagonists capable of inhibiting IL12/IL18 induced IFNγ production of blood cells and compositions and methods of use for said antibodies to treat pathological disorders that can be treated by inhibiting IFNγ production, IL12 and/IL23 signaling, such as rheumatoid arthritis, psoriasis or inflammatory bowel diseases or other autoimmune and inflammatory disorders. | 04-10-2014 |
| 20150361176 | LIGANDS THAT BIND TGF-BETA RECEPTOR II - The disclosure provides an anti-TGFbetaRII immunoglobulin single variable domain. Suitably, an anti-TGFbetaRII immunoglobulin single variable domain in accordance with the disclosure is one having an amino acid sequence as set forth in any one of SEQ ID NO:1-28 having up to 5 amino acid substitutions, deletions or additions. The disclosure further provides a polypeptide and pharmaceutical composition for treating a disease associated with TGFbeta signalling and suitably a disease selected from the group of: tissue fibrosis, such as pulmonary fibrosis, including idiopathic pulmonary fibrosis; liver fibrosis, including cirrhosis and chronic hepatitis; rheumatoid arthritis; ocular disorders; fibrosis of the skin, including keloid of skin; Dupuytren's Contracture; kidney fibrosis such as nephritis and nephrosclerosis; wound healing; scarring reduction; and a vascular condition, such as restenosis. | 12-17-2015 |
| 20160060345 | Novel EGFR-Binding Molecules and Immunoconjugates Thereof - Novel anti-cancer agents, including, but not limited to, antibodies and immunoconjugates, that bind to EGFR are provided. Methods of using the agents, antibodies, or immunoconjugates, such as methods of inhibiting tumor growth are further provided. | 03-03-2016 |
| 435335000 | Binds a lymphokine, cytokine, or other secreted growth regulatory factor, differentiation factor, intercellular mediator specific for a hematopoietic cell (e.g., interleukin, interferon, erythropoietin, etc.) | 8 |
| 20110091968 | MONOCLONAL ANTIBODY SPECIFIC TO BOTH HUMAN INTERFERON-ALPHA SUBTYPE ALPHA 8 AND ITS MUTANT PROTEINS - The present invention has the first object to provide a monoclonal antibody specific to interferon α subtype α8 (IFNα8) and its mutant proteins, the second object to provide a hybridoma capable of producing the monoclonal antibody, the third object to provide a method for detecting the IFNα8 and its mutant proteins by the monoclonal antibody, the fourth object to provide a method for purifying the IFNα8 and its mutant proteins by the monoclonal antibody, and the fifth object to provide a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8. The present invention solves the above objects by providing a monoclonal antibody specific to IFNα8 and its mutant proteins, a hybridoma capable of producing the monoclonal antibody, a method for detecting the IFNα8 and its mutant proteins by immunoreaction using the monoclonal antibody, a method for purifying the IFNα8 and its mutant proteins using the monoclonal antibody, and a therapeutic agent for treating diseases whose onsets or exacerbation are related with IFNα8, which contains the monoclonal antibody as an effective ingredient. | 04-21-2011 |
| 20120202285 | ANTIBODIES TO IL-6 AND THEIR USES - Antibodies and antigen-binding portions thereof that bind to human IL-6 are provided. Also provided are nucleic acids encoding such antibodies and antigen binding portions, methods of making such antibodies and antigen binding portions, compositions comprising such antibodies or antigen binding portions, and uses of such antibodies or antigen binding portions. | 08-09-2012 |
| 20130005033 | ANTIBODIES TO HUMAN IL-22 - The present application provides human antibodies and antigen binding fragments thereof that specifically bind to the human interleukin-22 (IL-22). The antibodies can act as antagonists of IL-22 activity, thereby modulating immune responses in general, and those mediated by IL-22 in particular. The disclosed compositions and methods may be used for example, in diagnosing, treating or preventing inflammatory disorders, autoimmune diseases, allergies, septic shock, infectious disorders, transplant rejection, cancer, and other immune system disorders. | 01-03-2013 |
| 20130071923 | HUMAN GM-CSF ANTIGEN BINDING PROTEINS - Antigen binding proteins that bind to human GM-CSF protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided. The antigen binding proteins can inhibit binding of GM-CSF to GM-CSFR, inhibit GM-CSF-induced proliferation and signaling of myeloid lineage cell lines and inhibit GM-CSF-induced activation of human monocytes. | 03-21-2013 |
| 20140186943 | NUCLEIC ACIDS ENCODING A HUMAN MONOCLONAL ANTIBODY THAT SPECIFICALLY BINDS TO IL-1a - Fully human monoclonal Abs includes (i) an antigen-binding variable region that exhibits very high binding affinity for IL-1α and (ii) a constant region that is effective at both activating the complement system though C1q binding and binding to several different Fc receptors. | 07-03-2014 |
| 20140377860 | Anti-Bv8 Antibodies and Uses Thereof - The present invention concerns antibodies to Bv8 and the uses of same. | 12-25-2014 |
| 20150353634 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 12-10-2015 |
| 20160186130 | CELL CULTURE IMPROVEMENTS - The invention describes improved methods and compositions for producing a recombinant protein, e.g., an antibody, in mammalian cell culture. In addition, the invention provides improved cell culture media, including improved production media, feed solutions, and combination feeds, which may be used to improve protein productivity in mammalian cell culture. | 06-30-2016 |
| 435336000 | Binds a hormone or other secreted growth regulatory factor, differentiation factor, intercellular mediator, or neurotransmitter (e.g., insulin, human chorionic gonadotropin, intragonadal regulatory protein, Mullerian inhibiting substance, inhibin, epidermal growth factor, nerve growth factor, dopamine, norepinephrine, etc.) | 3 |
| 20120142091 | Antibodies Against Human Angiopoietin 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 06-07-2012 |
| 20140065707 | ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2 - The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof. | 03-06-2014 |
| 20150299309 | PRODUCTION CELL LINE ENHANCERS - The present invention relates to discovery of the ectopic expression of EDEM2 in a production cell to improve the yield of a useful multi-subunit protein. Thus, the present invention provides for production cell lines, such as the canonical mammalian biopharmaceutical production cell—the CHO cell, containing recombinant polynucleotides encoding EDEM2. Also disclosed is a production cell containing both an EDEM2-encoding polynucleotide as well an XBP1-encoding polynucleotide. Improved titers of antibodies produced by these cell lines are disclosed, as well as the improved cell densities attained by these cells in culture. | 10-22-2015 |
| 435337000 | Binds a plasma protein, serum protein, or fibrin (e.g., clotting factor fibrinolytic factor, complement factor, immunoglobulin, apolipoprotein, etc.) | 2 |
| 20140162356 | MONOCLONAL ANTIBODIES WITH ENHANCED ADCC FUNCTION - The invention concerns a method for obtaining and selecting monoclonal antibodies by an ADDC-type test, said antibodies capable of activating type III Fcy receptors and having a particular glycan structure. The inventive anti-D antibodies can be used for preventing Rhesus isoimmunisation in Rh negative persons, in particular for haemolytic disease in a new-born baby of for uses such as idiopathic thrombocytopenic pupura 9ITP) | 06-12-2014 |
| 20150099298 | Antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and uses thereof - The present invention relates to antibodies capable of binding to the coagulation Factor XI and/or its activated form factor XIa and methods of use thereof, particularly methods of use as agents inhibiting platelet aggregation and by this inhibits thrombus formation. | 04-09-2015 |
| 435339000 | Binds a virus or component or product thereof (e.g., virus associated antigen, etc.) | 3 |
| 20100279400 | DIAGNOSTIC TEST FOR WEST NILE VIRUS - The present invention provides a rapid and sensitive method for the detection of a West Nile virus (WNV), Japanese encephalitis virus (JEV), St. Louis encephalitis virus (SLEV) and Dengue virus (DENV) and antibodies directed against thereof involving contacting a biological specimen suspected of being infected with WNV, JE, SLE or DEN with a substantially purified and isolated WNV E glycoprotein or subfragment thereof having a native conformation wherein the E glycoprotein or subfragment thereof has a reactivity with antibodies against WNV and a cross-reactivity with antibodies against JEV, SLEV and DENV. The instant invention further provides a rapid, sensitive, and consistent method for the specific detection of WNV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-WNV antibodies but not cross-reactive with antibodies against other flaviviruses such as JEV, SLEV, or DENV. The present invention also provides a rapid, sensitive, and consistent method for the specific detection of DENV by employing diagnostic assays having the antigen NS5 which is specifically reactive with anti-DENV antibodies but do not cross-react with antibodies against other flaviviruses such as JEV, SLEV, or WNV. Further, the DENV NS5 antigens are serospecific and do not cross react with antibodies to other DENV strains. Thus, the method of the present invention provides a manner by which to discriminate infections by each DENV strain. Further, diagnostic kits for carrying out the methods are provided. The methods and kits for carrying out the methods of the invention are rapid and require as little as 10 minutes to detect a result. The invention also provides monoclonal antibodies against WNV NS5 and DENV NS5 antigen and their use in detecting WNV and DENV infections in a biological sample. | 11-04-2010 |
| 20140302598 | HUMAN ANTIBODIES SPECIFICALLY BINDING TO THE HEPATITIS B VIRUS SURFACE ANTIGEN - Provided are antibodies specifically binding to the HBV surface antigen (HBsAg) which are effective for the prevention or treatment of hepatitis B. | 10-09-2014 |
| 435339100 | Binds a retrovirus or component or product thereof (e.g., HIV, LAV, HTLV, etc.) | 1 |
| 20140162357 | METHODS FOR GENERATION OF ANTIBODIES - This invention generally relates to methods for the production of antibody producing cells and antibodies in protooncogene expressing animals. The invention also relates to methods for the efficient production of antibodies specific for antigens that are normally subject to immunological constraints such as self tolerance. The invention further relates to the production of antibody producing cells and antibodies without the need for the conventional fusing of antibody producing B cells with a myeloma fusion partner. | 06-12-2014 |
| 435340000 | Binds a bacterium or similar microorganism or component or product thereof (e.g., Streptococcus, Legionella, Mycoplasma, bacterium associated antigen, exotoxin, etc.) | 4 |
| 20110275148 | HYBRIDOMA PRODUCING ANTIBODIES TO LAWSONIA INTRACELLULARIS - The present invention relates to the field of animal health and in particular to | 11-10-2011 |
| 20120196359 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-02-2012 |
| 20120208270 | POLY-N-ACETYL GLUCOSAMINE (PNAG/dPNAG)-BINDING PEPTIDES AND METHODS OF USE THEREOF - The present invention relates to peptides, particularly human monoclonal antibodies, that bind specifically to poly-N-acetyl glucosamine (PNAG), such as Staphylococcal PNAG, in acetylated, partially acetylated and/or fully deacetylated form. The invention further provides methods for using these peptides in the diagnosis, prophylaxis and therapy of infections by bacteria that express PNAG such as but not limited to Staphylococci and | 08-16-2012 |
| 20140120614 | ANTIBODIES AGAINST CLOSTRIDIUM DIFFICILE TOXINS AND USES THEREOF - Antibodies that specifically bind to toxins of | 05-01-2014 |
